AVTX Valuation

Avalo Therapeutics Inc

Add to Watchlist

Advanced Chart

4.900

-0.040(-0.810%)

Overview
Forecast
Valuation

AVTX Relative Valuation

AVTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AVTX is overvalued; if below, it's undervalued.

Historical Valuation

Avalo Therapeutics Inc (AVTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 241.90. The fair price of Avalo Therapeutics Inc (AVTX) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：4.90

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.39

P/B

Median3y

-2.43

Median5y

33.40

-93.05

FCF Yield

Median3y

-212.90

Median5y

-133.80

Competitors Valuation Multiple

The average P/S ratio for AVTX's competitors is 10.52, providing a benchmark for relative valuation. Avalo Therapeutics Inc Corp (AVTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -66.37%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

AVTX.O

Avalo Therapeutics Inc